Literature DB >> 9275147

Antibody to very late activation antigen 4 prevents interleukin-5-induced airway hyperresponsiveness and eosinophil infiltration in the airways of guinea pigs.

A D Kraneveld1, I van Ark, H J Van Der Linde, D Fattah, F P Nijkamp, A J Van Oosterhout.   

Abstract

This study examines the effect of monoclonal antibody to very late activation antigen-4 (VLA-4) on IL5-induced airway hyperresponsiveness in vivo and eosinophil accumulation into guinea pig airways. IL5 has been shown to be important in the development of airway hyperresponsiveness and eosinophil accumulation in the guinea pig. Eosinophils, unlike neutrophils, express VLA-4 which mediates the adhesion to vascular cell adhesion molecule-1 on endothelial cells. Thus VLA-4 seems to be an important adhesion molecule in the infiltration of eosinophils from the vasculature into the airway tissue. In addition, it has been shown that IL5 activates VLA-4 on eosinophils to facilitate their adhesion. In the present study, IL5 (1 microg, twice on one day) or vehicle were administered intranasally. Monoclonal antibody (mAb) to VLA-4 (HP1/2) or the isotype-matched control mAb (1E6) were injected 1 hour before each IL5 or vehicle treatment at a dose of 2.5 mg/kg body weight. The next day in vivo bronchial reactivity, eosinophil number in bronchoalveolar lavage (BAL) fluid, and eosinophil peroxidase (EPO) activity in cell-free BAL fluid were determined. IL5 induces an increase in bronchial reactivity to histamine, which is associated with an accumulation of eosinophils into BAL fluid (control: 12 (5 to 42) x 10(5) cells and IL5: 69 (11 to 99) x 10(5) cells, p < 0.05) and an increase of 35% +/- 14% in EPO activity in cell-free BAL fluid. Intravenous administration of anti-VLA-4 mAb, but not of the control antibody, completely inhibits the bronchial hyperresponsiveness as well as the airway eosinophilia found after intraairway application of IL5. HP1/2 also suppresses the IL5-induced increase in EPO activity in cell-free BAL fluid. In conclusion, for the development of IL5-induced airway hyperresponsiveness in the guinea pig, the VLA-4-dependent infiltration and activation of eosinophils in the bronchial tissue seems to be essential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9275147     DOI: 10.1016/s0091-6749(97)70231-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.

Authors:  Julio Cortijo; María-Jesús Sanz; Arantxa Iranzo; José Luis Montesinos; Yafa Naim Abu Nabah; José Alfón; Luis A Gómez; Manuel Merlos; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice.

Authors:  Nicholas J Kenyon; Ruiwu Liu; Erin M O'Roark; Wenzhe Huang; Li Peng; Kit S Lam
Journal:  Eur J Pharmacol       Date:  2008-12-13       Impact factor: 4.432

Review 3.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

Review 4.  Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma.

Authors:  Steven R Barthel; Mats W Johansson; Dawn M McNamee; Deane F Mosher
Journal:  J Leukoc Biol       Date:  2007-10-10       Impact factor: 4.962

Review 5.  Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease.

Authors:  P J Turner; J C Foreman
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

6.  Eosinophilic inflammation in allergic asthma.

Authors:  Samantha S Possa; Edna A Leick; Carla M Prado; Mílton A Martins; Iolanda F L C Tibério
Journal:  Front Pharmacol       Date:  2013-04-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.